Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
Eli Lilly & Co. (NYSE:LLY) has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded versions of the medication.
禮來公司（紐交所：LLY）正在加強對其備受歡迎的減肥藥物Zepbound的假冒版本進行打擊，對銷售混合版本該藥物的公司發起了額外的法律訴訟。
What Happened: The pharmaceutical company filed several new lawsuits on Thursday against various establishments, including medical spas and wellness centers, for promoting their products using Lilly's brand names, Mounjaro and Zepbound, reported Bloomberg. The company accused these businesses of trademark violations, false advertising, and unfair competition.
據彭博社報道，該藥品公司在週四針對多家機構提起了幾起新訴訟，包括醫療水療中心等，指責它們使用禮來的品牌名稱Mounjaro和Zepbound來推銷其產品。該公司指控這些企業侵犯商標權、虛假廣告和不正當競爭。
Lilly has initiated 11 legal actions, alleging trademark violations, false advertising, and unfair competition. These lawsuits target companies selling counterfeit drugs under the names tirzepatide, which is the generic name for Mounjaro, and Zepbound.
禮來公司已經發起了11起法律行動，指控涉嫌商標侵權、虛假廣告和不正當競爭，這些訴訟的目標是銷售以tirzepatide（即Mounjaro的通用名）和Zepbound的名稱所售出的假貨藥品的公司。
The U.S. regulators permit pharmacies to produce copycat versions of drugs that are in short supply, a practice known as compounding.
美國監管機構允許藥房製備缺貨的仿製藥，這種做法被稱爲混合製劑。
Lilly highlighted concerns about potential counterfeit products linked to tirzepatide, mentioning issues with safety, sterility, and efficacy. Some of these products reportedly contained bacteria, and impurities, or differed significantly from Lilly's FDA-approved medication.
禮來公司強調有關tirzepatide潛在假冒產品的擔憂，提到了安全、無菌和療效方面的問題。據報道，其中有些產品含有細菌、雜質或與禮來公司FDA批准的藥品明顯不同。
"In at least one instance, the product was nothing more than sugar alcohol," the company said.
該公司表示：“至少有一個產品只是糖醇而已。”
Why It Matters: This latest development comes after a series of strategic moves by Lilly to address the growing demand for its weight-loss and diabetes medications. In April, the company acquired a manufacturing facility from Nexus Pharmaceuticals to close the supply-demand gap for Zepbound and Mounjaro.
此次最新動態是禮來公司爲了應對其減肥和糖尿病藥物的增長需求而採取的一系列戰略舉措之後的。今年4月，該公司收購了Nexus Pharmaceuticals的製造設施，以填補Zepbound和Mounjaro的供需差距。
In May, it made its largest manufacturing investment in history to boost production for antidiabetic and weight-loss meds.
5月，它進行了有史以來最大的製造投資，以增加抗糖尿病和減肥藥物的生產。
Despite these efforts, the company has been facing challenges from counterfeit versions of its drugs. In May, Lilly reached a settlement agreement with a medical spa that sold counterfeit versions of Mounjaro and Zepbound. The spa agreed to pay a monetary settlement and cease using Lilly's branding to promote its products.
儘管採取了這些舉措，該公司仍面臨其藥品的假冒版本所帶來的挑戰。5月，禮來公司與一家售出Mounjaro和Zepbound假貨產品的醫療水療中心達成了和解協議。該水療中心同意支付一筆貨幣賠償並停止使用禮來的品牌爲其產品做宣傳。
These developments are significant in the context of the broader pharmaceutical industry. According to a report by Goldman Sachs, the global sales of weight-loss drugs are expected to reach $130 billion by 2030, with companies like Eli Lilly and Novo Nordisk (NYSE:NVO) leading the market.
這些發展對於整個製藥行業來說非常重要。根據高盛的一份報告，全球減肥藥品的銷售預計到2030年將達到1300億美元，其中像禮來公司和諾和諾德（紐交所：NVO）這樣的公司將佔據市場領先地位。
Price Action: Eli Lilly And Co's stock last closed at $891.46, up 0.73% for the day. In pre-market trading, the stock dipped 0.16%, according to data from Benzinga Pro.
股票交易方面，禮來公司股票上一次收盤價爲891.46美元，當天上漲0.73%。根據Benzinga Pro的數據，在美股盤前交易中，該股下跌0.16%。
Image Via Shutterstock
圖片來自shutterstock
This story was generated using Benzinga Neuro and edited by Kaustubh Bagalkote
本報道使用Benzinga Neuro生成，並由Kaustubh Bagalkote
譯文內容由第三人軟體翻譯。